Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II clinical trial of HPP737 in patients with moderate to severe psoriasis

Next Previous
Trial Profile

A phase II clinical trial of HPP737 in patients with moderate to severe psoriasis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HPP 737 (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Sponsors Newsoara Biopharma

Most Recent Events

  • 23 Sep 2021 According to a a vTv Therapeutics LLC media release, the company plans to file an IND application later this year for a 12-week Phase 2 clinical trial evaluating the safety and efficacy of HPP737 in patients with moderate to severe psoriasis with study initiation targeted for early 2022.
  • 04 Aug 2021 According to a vTv Therapeutics LLC media release, the company will discuss the proposed study design with the FDA during the third quarter and expect to begin the study late in the fourth quarter of 2021 or early in the first quarter of 2022.
  • 24 Feb 2021 According to a vTv Therapeutics LLC media release, the company expects to initiate this trial later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top